HPS Pharmacies prides itself on providing innovative and informative support to assist in the diverse range of issues health professionals face on a day-to-day basis, and to facilitate the distribution of this information for a variety of sectors within the healthcare industry.
HPS’ clinical articles are written by HPS Pharmacies’ experienced and knowledgeable staff and are peer-reviewed by specialist leaders in their field to ensure the accuracy of the information provided. The resourceful and diverse range of articles play an integral role in keeping all health professionals up-to-date with the happenings throughout the industry on a regular basis.
Dapagliflozin and empagliflozin are sodium-glucose co-transporter 2 (SGLT-2) inhibitors. These medications inhibit SGLT-2 in the renal proximal convoluted tubules. The SGLT-2 protein is responsible for the resorption of around 90% of the glucose from…
Read more
Potassium is an electrolyte which is essential for regulating nerve and muscle function, including cardiac muscle function. Disturbances in serum (blood) potassium affect the activity of Na/K – ATP pumps in the muscle tissue,…
Read more
Staphylococcus aureus is a gram-positive pathogen and is one of the major human pathogens with a tendency to develop resistant strains to antibiotics. A penicillin-binding protein, PBP-2a, is responsible for mediating the resistance…
Read more
Vulvovaginal candidiasis is a type of fungal infection characterized by inflammation of vagina and vulva caused by candida species. It is the second most common cause of vaginitis after bacterial vaginosis. Clinical presentation includes…
Read more
A new boxed warning is being added to the product information and consumer medicine information documents of systemic fluoroquinolone products. This warning advises that “fluoroquinolones… have been associated with disabling and potentially irreversible serious…
Read more
An updated consensus statement on the management of Buruli ulcer has recently been published. Buruli ulcer is a skin infection caused by the bacteria Mycobacterium ulcerans. This condition is named after the Buruli district…
Read moreSGLT-2 Inhibitors – Beyond Diabetes (May. 16 2025)
Hypokalaemia (May. 02 2025)
Fluoroquinolone Adverse Reactions (Mar. 20 2025)
Buruli Ulcer (Mar. 07 2025)
Reporting Adverse Events (Feb. 21 2025)
Pharmacogenomics (Feb. 07 2025)
National Standard for Chronic Obstructive Pulmonary Disease (Jan. 24 2025)
Urinary Tract Infections and Diabetes Mellitus (Jan. 10 2025)
Antiemetics (Dec. 27 2024)
Upcoming Changes to Paracetamol Scheduling (Dec. 13 2024)
Dementia Literacy (Nov. 29 2024)
Allergies and Antimicrobial Resistance (Nov. 15 2024)
Respiratory Syncytial Virus (Nov. 01 2024)
Antibiotic-Associated Diarrhoea (Oct. 18 2024)
Medicines and Breastfeeding (Oct. 04 2024)
Safe Use of High-Risk Medications (Sep. 20 2024)
Benzyl Alcohol in Pharmaceutical Products (Sep. 06 2024)
Semaglutide for Weight Management (Aug. 23 2024)
Medication-Induced Taste Disorders (Aug. 09 2024)
Respiratory Syncytial Virus (Jul. 26 2024)
Overview of cephalosporins (Jul. 05 2024)
Iron Infusions (Jun. 21 2024)
Sulfites in Pharmaceutical Products (Jun. 07 2024)
Potentially Inappropriate Medicines in the Australian Setting (May. 24 2024)
Intranasal Corticosteroids in Allergic Rhinitis (May. 10 2024)
Updated COVID-19 Vaccine Recommendations (Apr. 26 2024)
Medication-Overuse Headache (Apr. 12 2024)
Data and Decisions for the Three Different CDK4/6 Inhibitors (Mar. 29 2024)
Changes Affecting Submissions for Unapproved Therapeutic Goods (Mar. 15 2024)
Pneumoccoccal Vaccines (Mar. 01 2024)
Potential Anaesthesia Risk with GLP-1 Agonists (Feb. 16 2024)
Mycobacterium bovis BCG for Bladder Cancer (Feb. 02 2024)
Patient Deterioration in the Healthcare Setting (Jan. 19 2024)
Comparison of different types of G-CSF (Jan. 05 2024)
Medications for the Management of Urinary Incontinence (Dec. 22 2023)
Oral Therapies in Metastatic Prostate Cancer (Dec. 08 2023)
Antifungal Resistance (Nov. 24 2023)
Evidence-based Non-drug Treatments in Dementia – Reminiscence Therapy (Nov. 10 2023)
An Overview of Fungi (Oct. 27 2023)
Lower Urinary Tract Symptoms in Men (Oct. 13 2023)
Weight Loss Medications (Sep. 29 2023)
Revised Hip Fracture Clinical Care Standard (Sep. 15 2023)
Antibiotic Use in the Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (Sep. 01 2023)
Erythropoietin Resistance (Aug. 18 2023)
Amiodarone-induced Thyroid Disorders (Aug. 04 2023)
Biological Therapies for Rheumatoid Arthritis (Jul. 21 2023)
Mineralocorticoid Receptor Antagonists (Jul. 07 2023)
Neo-Adjuvant Treatment of Melanoma and Directed Therapy from the PRADO Trial (Jun. 23 2023)
Anticoagulant-Related Nephropathy (Jun. 09 2023)
Sepsis (May. 26 2023)
Patient Self-Management (May. 12 2023)
The Role of the Pharmacist in Survivorship Care (Apr. 28 2023)
Recurrent Urinary Tract Infections in Women (Apr. 14 2023)
Enerzair® Breezhaler® (Mar. 31 2023)
Tirzepatide: a New Treatment for Type 2 Diabetes and Weight Loss (Mar. 17 2023)
Vedolizumab and Ustekinumab for the Treatment of Crohn’s Disease (Mar. 03 2023)
Wernicke-Korsakoff Syndrome (Feb. 17 2023)
Gestational Diabetes (Feb. 03 2023)
Glucagon-like Peptide-1 Receptor Agonists (Jan. 20 2023)
The Clinical Merits Associated with Utilising a Prescribing Pharmacist (Jan. 06 2023)
Improving Medication Use at Transitions of Care (Dec. 23 2022)
Vericiguat for Heart Failure (Dec. 09 2022)
Probiotics for Preterm Infants (Nov. 25 2022)
Updated Recommendations for the Dosing of Anticancer Drugs in Kidney Dysfunction (Nov. 11 2022)
Solid Oral Dose Forms and Swallowing Difficulties (Oct. 28 2022)
Vancomycin Use in Arthroplasty Patients (Oct. 14 2022)
Drug Holidays from Bisphosphonates (Sep. 30 2022)
Iron Deficiency Anaemia (Sep. 16 2022)
Drug-induced QT Interval Prolongation (Sep. 02 2022)
Monkeypox in Australia (Aug. 19 2022)
Anticholinergic Burden (Aug. 05 2022)
New Therapy for Cystic Fibrosis (Apr. 29 2022)
Seasonal Influenza Vaccination (Apr. 14 2022)
Paroxysmal Nocturnal Haemoglobinuria (Apr. 01 2022)
Aged Care and Chemical Restraint (Mar. 18 2022)
Molnupiravir for COVID-19 (Mar. 04 2022)
SGLT2 Inhibitors for Heart Failure (Feb. 18 2022)
COVID-19 Treatment Options (Feb. 04 2022)
What is Cancer Survivorship Care? (Jan. 21 2022)
Managing the Side Effects of Chemotherapy (Dec. 31 2021)
COVID-19 Vaccine Boosters (Dec. 17 2021)
Glucagon-like Peptide-1 Analogues (Dec. 03 2021)
Antimicrobial Awareness Week (Nov. 18 2021)
Restless Legs Syndrome (Nov. 05 2021)
Medication Interactions with Food (Oct. 21 2021)
Revised Delirium Clinical Care Standard (Oct. 08 2021)
Hepatitis B Reactivation (Sep. 23 2021)
Antimicrobial resistance: The need for stewardship (Sep. 08 2021)
Cannabis (Aug. 26 2021)
Melanoma – An Update in Treatment Strategies (Aug. 13 2021)
New Labelling Standard (Jul. 30 2021)
Prevention of Shingles (Jul. 16 2021)
Melatonin down scheduling: a brief update (Jul. 01 2021)
Topical treatment in psoriasis (Jun. 17 2021)
Progress of Cervical Cancer Elimination (Jun. 04 2021)
New Action Plan for Pain Management (May. 21 2021)
Thyroid Awareness Month (May. 06 2021)
Influenza Vaccines (Apr. 23 2021)
Treatment of Eosinophilic Oesophagitis (Apr. 09 2021)
Hospital-initiated Medication Reviews (Feb. 26 2021)
Boxed Warnings for Gabapentinoids (Feb. 10 2021)
COVID-19 Vaccines (Jan. 28 2021)
Updates to the Poisons Standard (Jan. 15 2021)
Active Ingredient Prescribing (Dec. 23 2020)
New Digital Mental Health Standards (Dec. 18 2020)
Approval of New Prescription Medications (Dec. 04 2020)
Antimicrobial Resistance (Nov. 20 2020)
Vaccines and Cold Chain (Nov. 06 2020)
Darolutamide (Nubeqa®) in Prostate Cancer (Oct. 22 2020)
Drugs in Sport (Oct. 09 2020)
Treatment of Infantile Haemangioma (Sep. 25 2020)
Abemaciclib for Breast Cancer (Sep. 11 2020)
Primary Cutaneous T-cell Lymphoma (Aug. 28 2020)
Gliflozins and Heart Failure (Aug. 12 2020)
Remdesivir – an emerging treatment for COVID-19 patients. (Jul. 31 2020)
Safe Injection Practices (Jul. 17 2020)
Diabetes and Insulin (Jul. 02 2020)
Hydroxychloroquine as triple therapy in COVID-19 patients (Jun. 16 2020)
Tocilizumab, COVID-19 and the cytokine storm (Jun. 03 2020)
Colchicine use in Acute Myocardial Infarction (May. 20 2020)
Changes to Opioid PBS Listings (May. 06 2020)
Coronavirus Disease (Apr. 22 2020)
Risk of Viral Transmission with Nebulised Medication Delivery (Apr. 09 2020)
Xerostomia (Feb. 27 2020)
Monoclonal Antibodies for Migraine (Feb. 13 2020)
Changes to Neural Connector Devices (Jan. 30 2020)
Venetoclax (Jan. 16 2020)
Biosimilars in Oncology (Jan. 03 2020)
Prescription Opioid Changes (Nov. 22 2019)
Diabetes Medications in the Peri-Operative Period (Nov. 08 2019)
Lamotrigine Dose Escalation (Oct. 25 2019)
Wilson Disease (Oct. 11 2019)
Parkinson’s Disease and Hospitalisation (Sep. 27 2019)
Understanding Clinical Trials (Sep. 13 2019)
Short-Course Oxycodone Packs (Aug. 30 2019)
Tafenoquine: A Novel Anti-Malarial (Aug. 16 2019)
Medicinal Marijuana? (Aug. 02 2019)
Primary Prevention: a Low-Dose Aspirin Story (Jul. 19 2019)
Hand-Foot Syndrome (Jul. 08 2019)
Low Dose Methotrexate for Rheumatoid Arthritis (Jun. 21 2019)
Introduction to the storage of medications in a private hospital setting (Jun. 07 2019)
Lactulose for Hepatic Encephalopathy (May. 24 2019)
Proton Pump Inhibitor Restrictions (May. 10 2019)
Prevention of Recurrent Clostridium difficile Infection (Apr. 25 2019)
Updates to the Australian Asthma Handbook (Apr. 12 2019)
Heparins (Mar. 29 2019)
Safety and Quality Standards for Mental Health (Mar. 15 2019)
Potentially Harmful Medication Use in the Elderly (Mar. 01 2019)
Animal-Assisted Therapy for Dementia (Feb. 15 2019)
Augmented Renal Clearance (Feb. 01 2019)
Biofilms (Jan. 18 2019)
Medications and Sun Exposure (Jan. 04 2019)
